Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics today priced its public offering of about 9.3 million shares of its common stock at $0.75 per share. Interpace also granted the offering's underwriter a 30-day option to purchase up to an additional 1.4 million shares of its common stock at the public offering price. Gross proceeds from the offering, if the underwriter does not exercise that option, are expected to be about $7 million.

H.C. Wainwright is acting as the sole book-running manager for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.